Quiz Ref ID Intravenous thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) improves the outcome of patients with ischemic stroke treated within 4½ hours after symptom onset.
1 The most serious complication is symptomatic intracerebral hemorrhage (sICH), which was reported in 6% of patients with acute ischemic stroke in the National Institute of Neurological Disorders and Stroke rtPA trials.
2 Quiz Ref ID Despite its infrequent occurrence, sICH is associated with significant morbidity and a high mortality rate approaching 50%.
2 Recommendations by the American Heart Association and the American Stroke Association for the management of sICH are to replace coagulation factors with cryoprecipitate and to transfuse with platelets.
1 While prior studies
3-7 have investigated clinical and imaging risk factors for sICH, to our knowledge, the efficacy of these treatment recommendations has been examined in few investigations, which have been largely single-center studies.
8 Prior evidence has shown substantial variability in treatment practices and limited success in halting sICH.
8 These studies are limited by small sample sizes and incomplete accounting for confounders, such as code status change after sICH diagnosis. Therefore, we pooled contemporary data on treatment practices across several high-volume stroke centers in the United States with the objective to study the natural history of thrombolysis-related sICH, with a particular focus on the potential efficacy of various treatments. We also sought to identify key variables in the acute stroke treatment period that contributed to a high in-hospital mortality rate.